The intravenous immunoglobulin market in Europe is expected to grow from US$ 3,495.39 million in 2022 to US$ 5,363.10 million by 2028. It is estimated to grow at a CAGR of 7.4% from 2022 to 2028.
Rising Prevalence of Immunodeficiency Diseases
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most primary immunodeficiencies (PID). Rare genetic diseases can be chronic, weakening, and expensive to treat. Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets—a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, ~200,000 ITP cases are recorded across the region annually. Thus, the increasing prevalence of immunodeficiency diseases drives the intravenous immunoglobulin market.
Market Overview
Europe is the second largest market, owing to factors such as rise in the geriatric population, increase in the prevalence of immunodeficiencies and autoimmune diseases, and high demand for the development of new therapies in the region. In addition, growing funding for research & development activities is likely to add more opportunities in the region in the coming years. The pharmaceutical industry in Germany holds the fourth largest position with small and mid-sized companies. According to the International Trade Administration (ITA), in 2019, the pharmaceutical market in Germany accounted for US$ 62.5 billion. The country is likely to remain one of the most attractive destinations for the global pharmaceutical industry in the coming years in terms of manufacturing and supply. The industry's growth is driven by increasing investment in research and development and growing patent applications.
Local market players developing IVIg therapies are likely to favor market growth. For instance, Germany-based Biotest AG is developing polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases.
Europe Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
Europe Intravenous Immunoglobulin Market Segmentation
The Europe intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 3,495.39 Million |
| Market Size by 2028 | US$ 5,363.10 Million |
| CAGR (2022 - 2028) | 7.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
The Europe Intravenous Immunoglobulin Market is valued at US$ 3,495.39 Million in 2022, it is projected to reach US$ 5,363.10 Million by 2028.
As per our report Europe Intravenous Immunoglobulin Market, the market size is valued at US$ 3,495.39 Million in 2022, projecting it to reach US$ 5,363.10 Million by 2028. This translates to a CAGR of approximately 7.4% during the forecast period.
The Europe Intravenous Immunoglobulin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Intravenous Immunoglobulin Market report:
The Europe Intravenous Immunoglobulin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Intravenous Immunoglobulin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Intravenous Immunoglobulin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Europe Intravenous Immunoglobulin Market
